CRMD
CorMedix Inc.
CRMD trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CRMD overall, supported by lower modeled downside and stronger modeled upside.
CRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
CRMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.5x | $2.52 | -48% |
| Fair | 3.9x | $2.83 | -41% |
| Current | 6.6x | $4.84 | — |
| Expensive | 18x | $13.42 | +177% |
Historical ranges are pointers, not guarantees.
CRMD has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CRMD's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CRMD on the outlook, with more favorable earnings and revenue expectations.
CRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.73 | -65% |
| Q2 2026 | $2.18 | +179% |
| Q1 2026 | $2.17 | +768% |
| Q4 2025 | $2.04 | +$2.34 |
| Q3 2025 | $2.09 | +$2.89 |
| Q2 2025 | $0.78 | +$1.70 |
| Q1 2025 | $0.25 | +$1.17 |
| Q4 2024 | -$0.30 | +$0.61 |
CRMD earned $0.73 per share over the past year, down 65% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRMD on earnings, with more consistent year-over-year improvement.
CRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.5M | -48% |
| Q2 2026 | $101.9M | +157% |
| Q1 2026 | $127.4M | +226% |
| Q4 2025 | $128.6M | +312% |
| Q3 2025 | $104.3M | +810% |
| Q2 2025 | $39.7M | +4829% |
| Q4 2022 | $29.7K | -47% |
| Q3 2022 | $6.8K | -82% |
CRMD's revenue is growing: $55M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -61 points |
| Q2 2026 | 42% | -7.1 points |
| Q1 2026 | 50% | -1.5 points |
| Q4 2025 | 46% | +4.5 points |
| Q3 2025 | 49% | +78 points |
| Q2 2025 | 49% | +1947 points |
| Q1 2025 | 52% | N/A |
| Q4 2024 | 41% | N/A |
CRMD's operating margin was −12% last quarter, down 61 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CRMD on profitability, with a higher operating margin.
CRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.8M | +189% |
| Q2 2026 | $85.7M | +186% |
| Q1 2026 | $41.7M | +111% |
| Q4 2025 | $92.7M | +$98.4M |
| Q3 2025 | $30.4M | +$44M |
| Q2 2025 | $30M | +$44M |
| Q1 2025 | $19.7M | +$37.1M |
| Q4 2024 | -$5.6M | +$5.4M |
CRMD has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
CRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -15% | -14M shares |
| 1 year | +9.1% | +6.5M shares |
| 3 years | +73% | +33.1M shares |
| 5 years | +106% | +40.4M shares |
| Available history | +225% | +54.3M shares |
CRMD has 78M diluted shares, up 9.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $6.4M |
| Q1 2026 | $11.1M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -4.5x | Net Cash |
CRMD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 2.7 | Oversold |
CRMD's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRMD PE vs Healthcare Sector
| Metric | CRMD | Sector median | Relative |
|---|---|---|---|
| PE | 6.6x | 26x | 74% below |
| PE % | 66 | 29 | 37 pts above |
CRMD has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.67 | 27% below |
| 20 week MA | $7.49 | 35% below |
| 50 week MA | $7.91 | 39% below |
| 100 week MA | $9.41 | 49% below |
| 200 week MA | $7.22 | 33% below |
CRMD is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRMD on trend strength, trading above more of its moving averages.
CRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.14 | $7.87 | +10% |
| 2021 | $7.87 | $4.98 | -37% |
| 2022 | $4.98 | $4.11 | -17% |
| 2023 | $4.11 | $3.76 | -8.5% |
| 2024 | $3.76 | $8.21 | +118% |
| 2025 | $8.21 | $12.5 | +53% |
| 2026 YTD | $12.5 | $4.84 | -61% |
CRMD has finished lower in three of the last six years. It's down 61% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRMD on returns for 2026, with the stronger performance.